Dr. Reddys Laboratories is currently trading at Rs. 4706.35, down by 138.00 points or 2.85% from its previous closing of Rs. 4844.35 on the BSE.
The scrip opened at Rs. 4855.00 and has touched a high and low of Rs. 4875.85 and Rs. 4666.95 respectively. So far 1.28 lakh shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 5,613.65 on 07-Jul-2021 and a 52 week low of Rs. 4,019.65 on 28-Jul-2020.
Last one week high and low of the scrip stood at Rs. 5445.05 and Rs. 4666.95 respectively. The current market cap of the company is Rs. 88282.25 crore.
The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.93% and 17.06% respectively.
Dr. Reddy’s Laboratories has reported a fall of 56.49% in its net profit at Rs 413.40 crore for the quarter ended June 30, 2021 as compared to Rs 950.20 crore for the same quarter in the previous year. Total income of the company decreased by 6.93% at Rs 3619.70 crore for Q1FY22 as compared Rs 3889.10 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 36.02% in its net profit of associate at Rs 380.40 crore for the quarter ended June 30, 2021 as compared to Rs 594.60 crore for the same quarter in the previous year. However, total income of the company increased by 11.95% at Rs 5053.00 crore for Q1FY22 as compared Rs 4513.60 crore for the corresponding quarter previous year.